The Korea Times
Korea's main bourse operator said Thursday it is set to review a bio firm, whose stocks rallied recently amid hype over its weight-loss drugs and oral insulin, to determine whether the firm violated disclosure regulations. The Korea Exchange (KRX) said it has referred Sam Chun Dang Pharm Co., a local drugmaker, to its listing and disclosure committee for alleged failure to meet disclosure obligations. A final decision on whether the company violated disclosure regulations will be made next Thursday, according to the KRX. Stock prices of the pharmaceutical company rallied recently, as investor enthusiasm built around its next-generation drug pipeline, including oral insulin and a weight-loss drug. The company's share price had once surpassed the 1 million-won ($678.3) mark, becoming the first company since 2023 to reach the milestone on the secondary, venture-heavy Kosdaq market, according to the bourse operator. KRX, however, issued a prior notice late last month that the company may be designated as a violator of the disclosure regulation due to its failure to make fair disclosures regar
Go to News Site